- Home
- CNM vs MDGL Comparison
CNM vs MDGL Comparison
Compare CNM & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNM
- MDGL
- Stock Information
- Founded
- CNM 1996
- MDGL 2011
- Country
- CNM United States
- MDGL United States
- Employees
- CNM N/A
- MDGL N/A
- Industry
- CNM Durable Goods
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- CNM Consumer Discretionary
- MDGL Health Care
- Exchange
- CNM Nasdaq
- MDGL Nasdaq
- Market Cap
- CNM 9.9B
- MDGL 9.6B
- IPO Year
- CNM 2021
- MDGL N/A
- Fundamental
- Price
- CNM $52.78
- MDGL $423.00
- Analyst Decision
- CNM Buy
- MDGL Strong Buy
- Analyst Count
- CNM 11
- MDGL 12
- Target Price
- CNM $60.64
- MDGL $521.09
- AVG Volume (30 Days)
- CNM 2.2M
- MDGL 277.8K
- Earning Date
- CNM 12-02-2025
- MDGL 11-04-2025
- Dividend Yield
- CNM N/A
- MDGL N/A
- EPS Growth
- CNM 7.24
- MDGL N/A
- EPS
- CNM 2.25
- MDGL N/A
- Revenue
- CNM $7,740,000,000.00
- MDGL $515,547,000.00
- Revenue This Year
- CNM $4.45
- MDGL $394.38
- Revenue Next Year
- CNM $4.43
- MDGL $64.73
- P/E Ratio
- CNM $23.64
- MDGL N/A
- Revenue Growth
- CNM 11.02
- MDGL 3421.98
- 52 Week Low
- CNM $41.64
- MDGL $213.71
- 52 Week High
- CNM $67.18
- MDGL $463.63
- Technical
- Relative Strength Index (RSI)
- CNM 47.38
- MDGL 46.87
- Support Level
- CNM $52.41
- MDGL $393.61
- Resistance Level
- CNM $55.44
- MDGL $434.48
- Average True Range (ATR)
- CNM 1.54
- MDGL 16.23
- MACD
- CNM 0.39
- MDGL -2.55
- Stochastic Oscillator
- CNM 59.01
- MDGL 51.20
About CNM Core & Main Inc.
Core & Main is a leading specialty distributor with a focus on water, wastewater, storm drainage, and fire protection products. The company provides solutions to municipalities, private water companies, and professional contractors across municipal, nonresidential, and residential end markets. The company's specialty products and services are used in the maintenance, repair, replacement, and construction of water and fire protection infrastructure.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.